List of works - Ferenc Rick

A correlation of endocrine and anticancer effects of some antagonists of GHRH.

scientific article published on 13 July 2010

Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI)

scientific article published on 27 December 2011

Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema

scientific article published on 23 January 2012

Agonists of luteinizing hormone-releasing hormone in prostate cancer

scientific article published on 28 August 2013

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.

scientific article published on 16 April 2013

Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.

scientific article published on 4 November 2013

Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases

scientific article published on 18 January 2012

Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction

scientific journal article

Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers

scientific article

Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage

scientific article

Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.

scientific article

Hormonal manipulation of benign prostatic hyperplasia

scientific article published on January 2013

Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.

scientific article

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.

scientific article

LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia

scientific article published on 13 October 2010

Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia

scientific article

Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs

scientific article published on 15 July 2013

Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.

scientific article

Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists

scientific article published on 30 December 2013

Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.

scientific article published in October 2012

Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction

scientific article

Re: editorial comment on LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (Prostate 2011; 71: 736-747).

scientific article

Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist

scientific article published on 28 January 2013

Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.

scientific article published on February 2013

Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel

scholarly article

Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities

scientific article published on 25 December 2013

Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.

scientific article

Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives

scientific article published on May 2014

Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].

scientific article published in February 2013

The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.

scientific article published on 23 June 2011

List of works by Ferenc Rick

A correlation of endocrine and anticancer effects of some antagonists of GHRH.

Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI)

Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema

Agonists of luteinizing hormone-releasing hormone in prostate cancer

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.

Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.

Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases

Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction

Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers

Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage

Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.

Hormonal manipulation of benign prostatic hyperplasia

Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.

LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia

Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia

Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs

Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.

Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists

Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.

Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction

Re: editorial comment on LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (Prostate 2011; 71: 736-747).

Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist

Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.

Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel

Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities

Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.

Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives

Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].

The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.